Karna D Shinde invests in Navaux to transform early cancer detection

Navaux’s ACTIVH test predicts cancer onset years in advance and monitors treatment efficacy, providing real-time insights

0
111
New Delhi: Karna D Shinde, an early-stage angel investor, has made an investment in Navaux, a pioneering company based in Arkansas, USA, renowned for its advanced approach to early cancer detection through the ACTIVH blood test.
The ACTIVH test developed by Navaux can predict cancer onset up to 3-4 years ahead, based on preclinical research. This early detection tool enables individuals to make proactive lifestyle adjustments, such as quitting smoking or adopting healthier habits, potentially staving off cancer development.
Furthermore, the test offers critical real-time insights into the effectiveness of ongoing cancer treatments(chemotherapy, radiation, or other therapies) by monitoring Hepsin levels in the blood. A drop in Hepsin indicates successful treatment, while rising levels suggest the need for alternative strategies.
“Early cancer detection significantly improves survival rates.” said Karna D Shinde. “Navaux’s ACTIVH is a boon for patients and their families. Having witnessed the pain of cancer, I am proud that my investment supports a solution for the prevention and early diagnosis of this deadly disease. Determining aggressive cancer development before symptoms arise will lead to longer survival and a better quality of life for patients. Moreover, biomarkers like Hepsin offer the potential for future therapies that are more effective and produce fewer side effects.”
Hepsin has been a well-known marker in prostate cancer research for over a decade. Traditional detection methods struggled with identifying the active form of Hepsin. However, Navaux’s team has made significant progress by detecting activated Hepsin in bodily fluids, leading to the development of the ACTIVH liquid biopsy. This test, which is now validated, helps in early detection of metastasis, assessing risk, and monitoring treatment progress.
Don Fowler, CEO of Navaux, highlighted, “Karna’s involvement goes beyond financial support. His insights, dedication, and hands-on approach have been invaluable to our growth. Karna’s commitment to our mission at Navaux is a testament to his belief in our potential. We are incredibly fortunate to have such a dedicated partner.”
The ACTIVH test is designed to be quick, simple, and noninvasive, requiring only a blood sample to detect elevated Hepsin levels indicative of tumors. This method not only aids in early detection but also provides detailed information on tumor characteristics and possible metastasis. Compared to traditional methods, ACTIVH is more cost-effective and accessible, making early health management a reality for more people.
India is emerging as a significant player in health tech innovation, highlighted by Finance Minister Nirmala Sitharaman’s recent Union Budget 2024-25 announcement, which exempts key cancer treatment medications from customs duties to enhance accessibility. In this evolving landscape, Karna’s support is crucial for Navaux as they prepare to launch their revolutionary technology in the Indian healthcare market.
Navaux will also present new pre-clinical and clinical data on the potential of circulating Hepsin at the American Association for Cancer Research (AACR) conference.